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Fusidic  acid  is a topical  and  systemic  antimicrobial  used  for the treatment  of  staphylococcal  infections
in  hospitals  and  the  community.  Sales  of fusidic  acid  and  resistance  rates  among  meticillin-resistant
Staphylococcus  aureus  (MRSA)  doubled  between  1990  and  2001.  For  the  following  decade,  fusidic  acid
resistance  rates  among  isolates  from  Addenbrooke’s  Hospital  (Cambridge,  UK) were  compared  with
national  resistance  rates  from  MRSA  bacteraemia  surveillance  data  and  with  antimicrobial  sales  data.
Sales  of  fusidic  acid remained  relatively  constant  between  2002  and  2012,  whilst  fusidic  acid  resistance
increased  two-  and  four-fold  in  MRSA  bacteraemias  nationally  and  in  MRSA  isolates  from  Cambridge,
respectively.  A  subgroup  of  MRSA  resistant  only  to fusidic  acid increased  after 2006  by 5-fold  amongst
bacteraemias  nationally  and 17-fold  (to  7.7%  in  2012)  amongst  Cambridge  MRSA  isolates.  All  of the
available  local  isolates  from  2011  to  2012 (n = 23)  were  acquired  in  the  community,  were  not  related
epidemiologically  and  belonged  to multilocus  sequence  typing  (MLST)  groups  ST1,  5,  8,  45  or  149 as
revealed  from  analysis  of  whole-genome  sequence  data.  All  harboured  the  fusC  gene  on  one  of six dis-
tinct  staphylococcal  cassette  chromosome  (SCC)  elements,  four  of  which  were  dual-resistance  chimeras
that encoded  -lactam  and  fusidic  acid  resistance.  In  summary,  fusidic  acid-resistant  MRSA  increased
in prevalence  during  the  2000s  with  notable  rises  after  2006.  The  development  of chimeric  cassettes
that  confer  dual resistance  to -lactams  and  fusidic  acid demonstrates  that  the genetics  underpinning
resistance  in  community-associated  MRSA  are  evolving.
hew  J© 2015  Matt
. IntroductionThe emergence and dissemination of community-associated
eticillin-resistant Staphylococcus aureus (CA-MRSA) lineages in
he community [1] and hospital settings [2] pose a signiﬁcant clin-
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ical problem due to the lack of response to ﬁrst-line empirical
antimicrobials (-lactams). Alternative agents that can be easily
administered in either setting are required, particularly in light of
the fact that skin and soft-tissue infections (SSTIs) are now the
predominant known cause of MRSA bacteraemia in England (R.
Hope, personal communication). One option is fusidic acid, which
is licensed in Western Europe, Canada, Australia, New Zealand and
numerous countries in Asia (but not in the USA) [3] for the topi-
cal treatment of superﬁcial staphylococcal infections affecting the
skin and eye as well as for systemic administration for deep-seated
infections including those of the bones and joints.
The utility of fusidic acid depends on the rate of resistance,
which differs between countries [4,5]. For example, the rate of
nal Society of Chemotherapy. This is an open access article under the CC BY license
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esistance among S. aureus in 2007–2008 in the USA was only 0.3%
ompared with 7% in Canada and Australia and 11.8% in the UK [4,5].
usidic acid inhibits protein synthesis by preventing the turnover of
longation factor G (EF-G) from the ribosome, and resistance usu-
lly emerges through point mutation(s) in the chromosomal gene
ncoding EF-G (fusA), which typically confers high-level resistance
6]. More rarely, lower-level resistance can arise via the acquisi-
ion of factors that protect the translational machinery (encoded
y plasmid-borne genes fusB or fusC) [5,7].
Fusidic acid resistance among MRSA causing bacteraemia in the
K increased from 1.8% in 1990 to 5.5% in 2001, which accompa-
ied the increased use of this drug from 1.2 tonnes (t) to 3 t annually
uring the same period [8]. In this study, fusidic acid usage was
ompared with fusidic acid resistance rates in bacteraemia iso-
ates in the decade from 2002 in England. Fusidic acid resistance
n all MRSA (bacteraemia and non-bacteraemia) was  investigated
y examining data from patients admitted to Addenbrooke’s Hos-
ital in Cambridge (UK). This was complemented with a detailed
enomic investigation of the resistance mechanisms of MRSA iso-
ates that were resistant to fusidic acid but susceptible to the panel
f other drugs commonly tested. Speciﬁcally, the hypothesis that
usidic acid resistance had emerged and was disseminating via a
obile genetic element in one or more CA-MRSA lineages was
xamined.
. Methods
.1. Antimicrobial usage data, and local and national surveillance
ata
National antimicrobial prescription data collected by IMS  Health
London, UK) between 2002 and 2012 were supplied and ana-
ysed for changes in the amounts and proportions of the drug that
as sold. National surveillance data for MRSA bacteraemias sub-
itted by National Health Service (NHS) trusts to Public Health
ngland via the voluntary reporting system [9] between 2002 and
013 was accessed. From 2002 to 2013, the overall percentage
f MRSA reported with associated fusidic acid susceptibility data
as 76% (median annual percentage 80.8%, range 71.8–89.0%),
hilst the overall percentage with susceptibility data for fusidic
cid, a -lactam drug, erythromycin, ciproﬂoxacin, gentamicin and
etracycline was 38.1% (median annual percentage 51.9%, range
3.7–65.2%) (Supplementary Fig. S1). To examine local trends, the
icrobiology laboratory database at Cambridge University Hos-
itals NHS Foundation Trust (CUH) was accessed to identify all
atients who were MRSA-positive between 2002 and 2013. This
emonstrated that >90% of ﬁrst isolates of MRSA had been tested
or fusidic acid plus a -lactam drug, erythromycin, ciproﬂoxacin,
entamicin and tetracycline between 2002 and 2013 (Supplemen-
ary Fig. S1). Data were collected on the ﬁrst MRSA-positive sample
rom each case and included year of isolation, patient location at
he time of sampling and sample type. Cases with an MRSA iso-
ate that was resistant to fusidic acid but otherwise susceptible to
ther routinely tested drugs were identiﬁed and were expressed
s a proportion of the MRSA tested for fusidic acid per year (see
upplementary Fig. S1).
.2. Local clinical setting and microbiology
CUH is a 1000-bed secondary and tertiary referral hospital. The
n-site Clinical Microbiology and Public Health Laboratory pro-
ides diagnostic microbiology services to CUH, two additional NHS
rusts and three primary care trusts in the area. For CUH, ca. 600
00 clinical specimens are processed per year including screening
amples for MRSA, which since 2009 have been taken for all emer-
ency and elective admissions. Antimicrobial susceptibility testingntimicrobial Agents 45 (2015) 477–484
was performed by the diagnostic laboratory at CUH for cefoxitin,
erythromycin, ciproﬂoxacin, gentamicin, tetracycline, rifampicin,
fusidic acid and mupirocin using the disk diffusion method as
deﬁned by the British Society for Antimicrobial Chemotherapy [10].
Additional testing was performed using a VITEK® 2 instrument
(bioMérieux, Marcy-l’Étoile, France) to determine susceptibility
to oxacillin, trimethoprim/sulfamethoxazole, linezolid and tigecy-
cline as well as the minimum inhibitory concentration (MIC) to
fusidic acid.
2.3. Bacterial genome sequencing and sequence analysis
DNA was  extracted from S. aureus,  sequencing libraries
were prepared and whole-genome sequencing (WGS) was  per-
formed on an Illumina MiSeq instrument (Illumina Inc., San
Diego, CA) as previously described [11]. The genome data
have been deposited in the European Nucleotide Archive
(see Supplementary Table S1). Multilocus sequence typing
(MLST) types were assigned from the sequence data [11].
Having established the sequence type (ST), sequence reads
were mapped to the relevant reference genome representing
four STs (ST1, ST5, ST8 and ST45; accession nos. BX571857,
BA000018, CP000255 and BX571856, respectively) using SMALT
(https://www.sanger.ac.uk/resources/software/smalt/) [12]. Single
nucleotide polymorphisms (SNPs) were identiﬁed using a standard
approach by removing SNPs with low quality scores and by ﬁlter-
ing for SNPs that were present in ≥75% of the mapped reads [11].
Mobile genetic elements were excluded from the resulting whole-
genome alignments [13]. Genes encoding antimicrobial resistance
were detected by mapping a pseudomolecule that included the
known acquired fusidic acid resistance genes in S. aureus (Sup-
plementary Table S2) against de novo genome assemblies using
SMALT. This allowed the same gene to map  multiple times to the
assembly using 90% nucleotide identity as the cut-off for detection
as described previously [11]. Sequence reads were also mapped
against the susceptible variant of the fusA gene (encoding the
EF-G) to detect mutations conferring resistance towards fusidic
acid. Staphylococcal cassette chromosome (SCC) regions were visu-
alised (including sequence coverage and SNP variations) using
Artemis [14] and were compared using the Artemis Comparison
Tool. The fusC-encoding region in the ST8 isolate (MRSA18) was
highly fragmented and was  not analysed further. Maximum likeli-
hood phylogenies of the SCCs were estimated using RAxML [13].
3. Results
3.1. Trends in fusidic acid sales and MRSA fusidic acid resistance
The amount of fusidic acid prescribed annually in the UK was rel-
atively constant at ca. 3 t between 2002 and 2009, with a decrease
to 2.5 t in 2012 (Fig. 1A). The majority (78–85%) of fusidic acid was
prescribed in the community, of which between 82% and 90% was
for topical use (Fig. 1A). By contrast, topical preparations accounted
for 9–13% of fusidic acid sales in the hospital (data not shown).
Contrary to the modest decline in overall sales of fusidic acid, the
percentage of fusidic acid resistance amongst MRSA bacteraemia
isolates in England approximately doubled over the same time
period (Fig. 1B). Notably, MRSA bacteraemia isolates that were only
resistant to fusidic acid but were otherwise susceptible were not
detected in 2002 but steadily increased in number to reach to 2.4%
of MRSA bacteraemia isolates by 2012 and 3.9% in 2013 (Fig. 1B).
These increases occurred in the context of a six-fold decrease in
national MRSA bacteraemias, from a peak of 5522 cases in 2003 to
887 cases in 2013 (Fig. 1B).
To investigate whether these bacteraemia surveillance data
were representative for MRSA isolated from other sample sites, the
M.J. Ellington et al. / International Journal of A
Fig. 1. Trends in fusidic acid-resistant meticillin-resistant Staphylococcus aureus
(MRSA) rates and fusidic acid sales between 2002 and 2013. (A) Percentage of fusidic
acid prescribed in the UK for topical use (blue bars) and systemic use (red bars) in
the community, and for hospital use (grey bars). These are shown as a proportion
of  the total drug sold (black line). (B) Number of MRSA bacteraemias in England
(black line), the percentage that were resistant to fusidic acid regardless of other
antimicrobials (light purple), and the percentage resistant to fusidic acid only (dark
purple). (C) The number of MRSA isolated from any body site at Cambridge Univer-
sity Hospitals NHS Foundation Trust (black line), the percentage of the total MRSA
that were resistant to fusidic acid regardless of other antimicrobials (pink), and the
percentage of MRSA resistant to fusidic acid only (red). The percentages in (B) and (C)
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oere  calculated for those isolates for which antimicrobial susceptibility data were
vailable (Supplementary Fig. S1). The bars represent 95% conﬁdence intervals. The
umber of cases associated with each data point in (B) and (C) are shown.
icrobiology database at CUH was interrogated. The prevalence of
usidic resistance amongst all MRSA isolated in our centre quadru-
led from 5.4% in 2002 (Fig. 1C), supported by a two- to three-fold
ncrease in the number of cases. The proportion of MRSA that were
nly resistant to fusidic acid increased from 0.2% in 2006 to just
ver 7% in 2013, supported by a ≥10-fold increase in the number
f cases. During the same period, total MRSA cases at CUH (positiventimicrobial Agents 45 (2015) 477–484 479
from any sample, including carriage) more than halved from a peak
of 1270 cases in 2007 to 584 cases in 2013.
3.2. Emergence of multiple community-associated MRSA lineages
with fusidic acid resistance
To investigate whether the large increase in MRSA that were
only resistant to fusidic acid (fusidic acid-mono-resistant MRSA)
was due to the expansion of a particular clone, all of the available
fusidic acid-mono-resistant MRSA isolates that were isolated and
stored at CUH during a period of 14 months starting in November
2011 were sequenced [23 available out of a possible 27, all from
different patients (P1–P23)]. Meticillin resistance but susceptibil-
ity to other routinely tested drugs is often indicative of CA-MRSA
[15]. Examination of the hospital databases revealed that the 23
patients had been admitted to a range of clinical specialities at CUH.
The majority (n = 15) had no prior visit to hospital within the pre-
ceding 12 months, all but 1 case (P8) was  MRSA-positive within 48 h
of admission, and the median age was low for MRSA carriage (30
years) (Table 1). From this, we concluded that these were sporadic
cases and that MRSA colonisation was likely to have originated in
the community.
Genetic investigation using WGS  revealed that the 23 isolates
(designated MRSA1 to MRSA23) from these patients were associ-
ated with six different STs from four clonal complexes (CCs) [CC1
(ST1); CC5 [ST5, 149 and 2942 (a single-locus variant of ST149)];
CC45 (ST45); and CC8 (ST8)] (Table 1), demonstrating that mul-
tiple lineages of fusidic acid-mono-resistant MRSA had arisen via
independent genetic events. Of these STs, ﬁve have been reported
previously to contain examples of CA-MRSA [16–19]. The related-
ness of isolates belonging to the same ST was then investigated by
mapping the genomes to a reference genome of the same MLST CC.
The two  most closely related isolates (MRSA15 and MRSA17, both
ST149), isolated 8 weeks apart from paediatric urology and adult
oncology patients, respectively, were distinguished by 14 SNPs dis-
tributed throughout the core genome (Supplementary Table S3). An
estimate based on a similar mutation rate identiﬁed in S. aureus [20]
suggests that these two isolates diverged from a common ancestor
over ca. 16 months. These ﬁndings are indicative of sporadic MRSA
carriage, with no evidence for direct transmission links.
3.3. Genetic basis for fusidic acid resistance
Despite being genetically disparate, all of the isolates were
classiﬁed as having low-level resistance to fusidic acid (MICs of
2–64 mg/L), which is consistent with a transferable resistance
mechanism [6,7]. This proved to be the case, since all isolates were
positive for fusC and had wild-type fusA. The genetic regions around
fusC showed that this gene resided within SCC elements, which are
most widely known for harbouring the -lactam resistance gene
mecA. Visualisation of the gene content and order within the fusC-
encoding cassettes revealed six different types of SCC that belonged
to two  distinct classes [21].
The ﬁrst class contained two  of the six fusC-encoding SCCs,
which were adjacent to an SCCmecIV [22,23] element forming large
composite islands (Fig. 2A). These two  composite islands were each
unique to a speciﬁc lineage (ST1 or ST149/ST2942) (Table 2) and dif-
fered in size (45 kb vs. 42 kb, respectively). Within each island, the
SCC elements were each ﬂanked by direct repeat sequences (DRscc)
that demarcated the individual cassettes [23]. A phylogenetic anal-
ysis of the 10 isolates with these composite islands indicated that
the fusC SCC elements were almost identical within a given ST
(maximum difference of two SNPs) (Fig. 2B). A comparison was  per-
formed between these and previously described composite islands.
The cassette in the ST1 isolates (with the exception of MRSA3, see
below) was identical to the previously described SCC476 (Fig. 2B;
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Table  1
Clinical characteristics of patients positive for meticillin-resistant Staphylococcus aureus (MRSA) at Addenbrooke’s Hospital (Cambridge, UK).
Patient no./isolate no. Age (years) Specialty Reason for
presentation
History of skin
disease
MRSA isolated
within 48 h of
admission
Hospital
contact in
previous 12
months
Isolate
sequence
type
P1/MRSA1 4 Paediatric ENT Elective
surgery
+ + − ST149
P2/MRSA2 22 General
surgery
Biliary colic − + − ST1
P3/MRSA3 20 Obstetrics Childbirth − + − ST1
P4/MRSA4 70 Cardiology Arrhythmia − + − ST149
P5/MRSA5 36 ENT Elective
surgery
− + + ST2942
P6/MRSA6 83 Orthopaedics Elective
surgery
− + − ST1
P7/MRSA7 44 General
medicine
Chest pain − + + ST5
P8/MRSA8 69 Cardiology Chest pain + − + ST45
P9/MRSA9 19 General
surgery
Acute pain − + − ST45
P10/MRSA10 19 A&E Deep vein
thrombosis
+  + − ST5
P11/MRSA11 27 ENT Elective
surgery
− + − ST45
P12/MRSA12 49 Plastics Elective
surgery
− + − ST45
P13/MRSA13 21 ENT Elective
surgery
− + − ST149
P14/MRSA14 41 A&E Trauma − + − ST1
P15/MRSA15 5 Paediatric
urology
Elective
surgery
− + − ST149
P16/MRSA16 47 ENT Elective
surgery
− + − ST45
P17/MRSA17 54 Oncology Day case − + + ST149
P18/MRSA18 40 Obstetrics Childbirth + + + ST8
P19/MRSA19 30 Obstetrics Childbirth − + − ST45
P20/MRSA20 2 Paediatric
dermatology
Recurrent
eczema
+ + − ST45
P21/MRSA21 73 Oncology Day case + + + ST45
P22/MRSA22 27 Obstetrics Childbirth − + + ST1
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SP23/MRSA23 19 A&E Trauma 
NT, ear, nose and throat; A&E, accident and emergency.
able 2), whereas the cassette that encoded fusC in ST149 was  novel
ompared with both of the previously described fusC-encoding SCC
lements (SCC476 and SCCfusC) [24,25].
The second class contained the four remaining genetic ele-
ents, which consisted of a single fused, or chimeric, SCC element
hat contained both the mecA and fusC resistance genes, rather
han two adjacent SCC elements. These elements were 18–25 kb
n size, were ﬂanked by single DRscc sequences at either end
f the cassette and were designated SCCmec-fus I–IV (Fig. 3A).
hylogenetic analysis of these chimeric elements showed that
T45 and ST1 each carried a unique cassette but that isolates
ithin the same ST carried the same element. By contrast, ST5
solates carried two different cassettes (Fig. 3B; Table 2). The
ecA or fusC portions of the cassettes matched the correspond-
ng parts of SCCmecIV and SCC476 in the public sequence database
able 2
ix genetic elements associated with meticillin and fusidic acid resistance.
Cassette Sequence type Patient 
Composite islands (two adjacent SCCs, encoding either fusC or mecA)
SCC476 and SCCmecIVa ST1 MRSA2,
SCCmecIVa and SCC149 ST149 + 2942 MRSA1,
Chimeric cassettes (single cassettes encoding both fusC and mecA)
SCCmec-fus I ST1 MRSA3 
SCCmec-fus  II ST5 MRSA7 
SCCmec-fus  III ST5 MRSA10
SCCmec-fus  IV ST45 MRSA8,
CC, staphylococcal cassette chromosome; N/A, not applicable.− + + ST45
(GenBank, 2 September 2014), but we found no cassettes that
encoded mecA and fusC within the same compact and complete SCC
region.
In the chimeric element from isolate MRSA3 (SCCmec-fus I),
a 32-bp region that was  present in both SCCmecIVa and SCC476
was identiﬁed ((1) and (2) in Fig. 3A), but was in single copy
in SCCmec-fus I. This region was ﬂanked to the left by DNA that
was identical to SCCmecIVa and to the right by DNA that was
identical to SCC476. We  propose that homologous recombination
involving this region led to the junction (“(1)/(2)” in Fig. 3A) and
the resultant recombined element SCCmec-fus I. The other cas-
settes, SCCmec-fus II–IV, showed different homology patterns to
the SCCmec-like and the SCC476 cassettes, indicating independent
recombination events that have created new chimeric resistance
cassettes in MRSA.
isolates Closest published homologues
 6, 14, 22 SCC476 [24] and SCCmecIVa [22]
 4, 5, 13, 15, 17 SCCmecIVa [22] and SCCfusC [25]
N/A
N/A
 N/A
 9, 11, 12, 16, 19, 20, 21, 23 N/A
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Fig. 2. Comparative and phylogenetic analyses of composite islands encoding mecA and fusC. (A) Staphylococcal cassette chromosome (SCC) elements that encode fusC as
the  only antimicrobial resistance (in teal) were adjacent to a second SCC (SCCmecIV, in grey) in composite islands in ST1 and ST149 (and its single-locus variant ST2942).
The  direct repeat sequences (DRscc) that delimit each SCC are shown as vertical red lines topped by a black square. (B) Phylogenetic analysis and comparison with previously
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sdentiﬁed cassettes SCC476 and SCCfusC (in black) identiﬁes two  distinct SCCs that 
T149  isolates was  designated SCC149.
. Discussion
More than 50 years since the ﬁrst use of fusidic acid, we describe
ew trends in fusidic acid resistance. MRSA resistant only to fusidic
cid increased in prevalence and number between 2002 and 2013.
his coincided with the spread of fusC on various horizontally
ransferred chromosomal cassettes, including the newly described
CCmec-fus chimeric cassettes, in genetically diverse CA-MRSA.
Current data suggest recent global spread of fusC MRSA, with
n association with the epidemic ST239 clone in Taiwan [25], and
he emergence of diverse fusC MRSA in New Zealand following
ncreased usage of fusidic acid since 2000 [26]. Previous UK data
ave shown that between 1990 and 2001 annual sales of this drug
ore than doubled from 1.2 t to 3 t [8], whilst fusidic acid resis-
ance in MRSA in UK bacteraemia isolates increased from 1.8% to
.5%. In this study, we examined the decade from 2002, during
hich the epidemiology of MRSA in the UK changed signiﬁcantly.
fforts to control hospital-associated MRSA (HA-MRSA) and the
ubsequent reduction in MRSA bacteraemias since 2007 may  have
educed the dissemination of HA-MRSA beyond healthcare settings
ut has been associated with an expansion of CA-MRSA in the com-
unity setting. Fusidic acid sales remained at ca. 3 t until 2009
nd subsequently decreased, mostly due to decreased use in hospi-
als. Nevertheless, fusidic acid resistance amongst MRSA increased
o ca. 20%. This is likely to result in more failures of fusidic acid
reatment for superﬁcial infections in the community [27,28]. Sub-
equent empirical systemic treatments (i.e. with -lactams and
rior to culture) will also likely fail and may  then result in more
evere and disseminated infection. This is of particular relevanceunique to ST1 in purple (SCC476) or ST149 in green. The novel cassette in found in
given that SSTIs have become the leading source of bacteraemia in
England since 2009 (R. Hope, personal communication). This asso-
ciation with SSTIs was  consistent with data from CUH, where the
majority (71%) of samples taken for clinical reasons (i.e. not includ-
ing screening samples) were from skin or soft tissue. fusC accounted
for all of the fusidic acid resistance detected amongst these emer-
gent and genetically diverse MRSA, demonstrating that, regardless
of other mechanisms, fusC is highly disseminated. fusC was found on
six different genetic elements, including four elements that were
chimeras of two  SCCs, one encoding fusC and the other encoding
-lactam resistance (mecA). These new SCCmec-fus cassettes were
compact dual-resistance cassettes that are deﬁned by normal SCC
borders and encoded the machinery necessary for mobilisation.
This new mechanism for the accrual of drug resistances into a single
compact element has the potential to efﬁciently transfer multiple
resistance genes and could lead to further increases in multidrug
resistance amongst S. aureus,  effectively breathing new life into
the evolution of MRSA. This bears a resemblance to the accumu-
lation of drug resistance in Gram-negative bacteria. These genetic
rearrangements would have been difﬁcult, if not impossible, to
dissect in detail using traditional technologies such as PCR and
DNA–DNA hybridisation currently employed for routine molec-
ular epidemiological surveillance. This highlights the importance
of introducing routine WGS  to complement and enhance existing
surveillance schemes.These ﬁndings have two important implications for antibiotic
stewardship. First, they reinforce the hazards of using valuable
systemic antimicrobials as topical agents widely in the community
[29]. The convenience of topical therapy needs to be balanced
482 M.J. Ellington et al. / International Journal of Antimicrobial Agents 45 (2015) 477–484
Fig. 3. Comparative and phylogenetic analyses of fused staphylococcal cassette chromosome (SCC) elements encoding both fusC and mecA. (A) SCC elements were formed
from  portions of SCCmec (in grey) and SCC476-like cassettes (in teal) and were ﬂanked by direct repeat sequences (DRscc). Percentage DNA sequence homologies to the
corresponding portion of SCCmecIVa or SCC476 are shown above each SCCmec-fus. The change in sequence homology from SCCmec  to SCC476 (denoted and detailed by red
n s). (B
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cumbers in red circles) occurred within coding sequences (shown as red arrow head
n  cyan and ST45 in orange. The reference cassettes SCC476 and SCCfusC are shown i
gainst the risk of promoting resistance. We  believe that it is sensi-
le to restrict the use of topical fusidic acid to short courses and to
void intermittent use [30] for patients outside hospital, together
ith close monitoring of local antibiotic susceptibility patterns
or evidence of the further spread of fusidic acid-resistant MRSA.
econd, traditional approaches to combat antimicrobial resistance,
uch as decreasing the use of a drug in order to reduce selective
ressure, may  not be effective based on the current ﬁndings.
his strategy relies upon different resistance mechanisms being
enetically independent of each other. By contrast, genetically
inked resistances, such as those we describe, will be co-selected
y multiple drugs and any strategies to switch or rotate antimi-
robial usage must therefore take account of genetically linked) Four different SCCs were identiﬁed and were unique to ST1 in purple (SCC476), ST5
k.
resistances. Most treatment guidelines are based on phenotypic
resistance rates alone and consider each antimicrobial class as a
discrete unit, further underscoring the value associated with the
routine use of WGS  for surveillance purposes.
5. Conclusions
Fusidic acid resistance amongst MRSA underwent a rapid
increase after 2008, more than 50 years after its ﬁrst use. The
heaviest use of fusidic acid occurred in the community, where
diverse MRSA that were only resistant to fusidic acid were emerg-
ing rapidly, with both known and novel SCCs. The observation
of four distinct SCCs that have evolved as chimeras of multiple
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rogenitor cassettes to create compact (<25 kb) dual antimicro-
ial resistance (SCCs) signals a new mechanism underpinning
he development of MRSA and the accrual of multiple resistance
enes in S. aureus.  The cumulative evidence supports the premise
hat use of fusidic acid in the community is driving the selection
f fusC-encoding cassettes, including composite SCCmec-fus cas-
ettes that can become introduced into hospitals, and highlights
he need to control MRSA both in the hospital and community
ettings.
These ﬁndings illustrate the value of combining macro data
i.e. antimicrobial sales and national surveillance data) with local
ata and targeted molecular investigations that use WGS  to dis-
ect changes in MRSA epidemiology. The information we gain with
hese approaches will help to inform future control strategies for
RSA as it continues to change.
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